Expression of class III β-tubulin in colorectal carcinomas: An immunohistochemical study using TU-20 & TuJ-1 antibody

Indian Journal of Medical Research

Volumn 129, Issue 1, 2009, Pages 89-94

  Jirásek, Tomáš ^a   Cipro, Šimon ^a   Musilova A ^a   Kubecova M ^a   Mandys, V ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Class III tubulin; Colorectal cancer

Indexed keywords

BETA TUBULIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TU20; MONOCLONAL ANTIBODY TUJ-1; PACLITAXEL DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RESISTANCE; CELL POPULATION; COLORECTAL CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; TUBULIN;

EID: 65949090282     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Sullivan KF. Structure and utilization of tubulin isotypes. Annu Rev Cell Biol 1988; 4: 687-716.
2. Draberova E, Lukas Z, Ivanyi D, Viklicky V, Draber P. Expression of class III beta-tubulin in normal and neoplastic human tissues. Histochem Cell Biol 1998; 109: 231-9.
3. Katsetos CD, Herman MM, Mork SJ. Class III beta-tubulin in human development and cancer. Cell Motil Cytoskeleton 2003; 55: 77-96.
4. Dumontet C, Isaac S, Souquet PJ, Bejui-Thivolet F, Pacheco Y, Peloux N, et al. Expression of class III beta tubulin in nonsmall cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 2005; 92: E25-30.
5. Ferlini C, Raspaglio G, Mozzetti S, Cicchillitti L, Filippetti F, Gallo D, et al. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res 2005; 65: 2397-405.
6. Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005; 11: 298-305.
7. Shalli K, Brown I, Heys SD, Schofield AC. Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J 2005; 19: 1299-301.
8. Easter SS, Jr., Ross LS, Frankfurter A. Initial tract formation in the mouse brain. J Neurosci 1993; 13: 285-99.
9. Katsetos CD, Frankfurter A, Christakos S, Mancall EL, Vlachos IN, Urich H. Differential localization of class III, beta-tubulin isotype and calbindin-D28k defines distinct neuronal types in the developing human cerebellar cortex. J Neuropathol Exp Neurol 1993; 52: 655-66.
10. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005; 6: 229-39.
11. Katsetos CD, Legido A, Perentes E, Mork SJ. Class III beta-tubulin isotype: a key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology. J Child Neurol 2003; 18: 851-66; discussion 67.
12. Jirasek T, Pisarikova E, Viklicky V, Mandys V. Expression of class III 2-tubulin in malignant epithelial tumours: an immunohistochemical study using TU-20 and TuJ-1 antibodies. Folia Histochem Cytobiol 2007; 45: 41-5.
13. Hamilton SR, Vogelstein B, Kudo S, Riboli E, Nakamura S, Hainaut P, et al. Tumours of the Colon and Rectum. In: Hamilton SR, Aaltonen LA, editors. World Health Organization classification of tumours pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000. p. 104-43.
14. Jirasek T, Mandys V. Immunohistochemical Expression of Chromogranin A and Leu-7 in Gastrointestinal Carcinoids. In: Hayat MA, editor. Handbook of immunohistochemistry and in situ hybridization of human carcinomas vol. IV, molecular genetics, gastrointestinal carcinoma, and ovarian carcinoma. San Diego: Elsevier Academic Press; 2006. p. 183-90.
15. Katsetos CD, Herman MM, Frankfurter A, Gass P, Collins VP, Walker CC, et al. Cerebellar desmoplastic medulloblastomas. A further immunohistochemical characterization of the reticulin-free pale islands. Arch Pathol Lab Med 1989; 113: 1019-29.
16. Jirasek T, Mandys V, Viklicky V. Expression of class III beta-tubulin in neuroendocrine tumours of gastrointestinal tract. Folia Histochem Cytobiol 2002; 40: 305-10.
17. Katsetos CD, Kontogeorgos G, Geddes JF, Herman MM, Tsimara-Papastamatiou H, Yu Y, et al. Differential distribution of the neuron-associated class III beta-tubulin in neuroendocrine lung tumors. Arch Pathol Lab Med 2000; 124: 535-44.
18. Eberlein-Gonska M, Wiedenmann B, Waldherr R. Synaptophysin, chromogranin A and neuron-specific enolase as tumor markers in neuroendocrine tumors of the gastrointestinal tract and lung. An immunohistochemical study. Pathologe 1989; 10: 228-33.
19. Verrills NM, Flemming CL, Liu M, Ivery MT, Cobon GS, Norris MD, et al. Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. Chem Biol 2003; 10: 597-607.
20. De Vita VT, Hellman S, Rosenberg SA. Pharmacology of cancer chemotherapy. Cancer - Principles and practice of oncology. 7th ed Philadelphia: Lippincott Williams & Wilkins; 2005.
21. Pagani A, Papotti M, Abbona GC, Bussolati G. Chromogranin gene expressions in colorectal adenocarcinomas. Mod Pathol 1995; 8: 626-32.